Varubi (Rolapitant HCl) Patent Expiration, LOE Window & CMS Spending

Varubi (Rolapitant HCl) by Tersera Therapeutics: FDA Orange Book core substance LOE 2028-08-19 (last listed 2029-10-09), 0 AB generics, $533K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTersera Therapeutics
FDA Application & PathwayN206500 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2028-08-19
Last Listed Patent or Exclusivity Date2029-10-09
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$533K
2024 Medicare Part D Spend$533K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel